Compositions and methods for treating and preventing coronary heart disease
AssigneeBoston Heart Diagnostics Corporation
InventorsErnst J. Schaefer, Eliana Polisecki
Life of this patent
Estimating the term…
Abstract
The invention pertains to a method of determining a statin dosage for an individual in need of treatment with a statin, comprising determining a SLCO1B1 genotype from a nucleic acid sample of the individual, said genotype comprising the presence or absence of the SLCO1B1-056 polymorphism, and determining an ApoE genotype or phenotype identifying an ApoE polymorphism selected from the group consisting of ApoE2, ApoE3, ApoE4, and any combination thereof, wherein the combination of a SLCO1B1 genotype identifying the presence of the SLCO1B1-056 C polymorphism and the ApoE genotype or phenotype identifying one of the ApoE3/4 or ApoE4/4 genotypes indicates the statin dosage.
Claims20
-20. (canceled)
A method of characterizing a subject's response to a cholesterol lowering therapy, the method comprising:
- determining a level of cholesterol in a sample obtained from a patient;
- conducting an assay in the sample to identify a polymorphism associated with statin efficacy, wherein the polymorphism is selected from the group consisting of a SLCO1B1 polymorphism, an Apolipoprotein E (ApoE) polymorphism, and a combination of a SLCO1B1 polymorphism and an ApoE polymorphism;
- establishing weighted values based on the level of cholesterol and a genotype of the polymorphism;
- characterizing said patient's likelihood of responding to a cholesterol lowering therapy based on said weighted values.
A method of determining a cholesterol lowering therapy of a subject, the method comprising:
- determining a level of cholesterol in a sample obtained from a patient;
- conducting an assay in the sample to identify the presence or absence of a biomarker associated with statin efficacy, wherein the biomarker is one or more genes selected from the group consisting of SLCO1B1 and Apolipoprotein E (ApoE);
- establishing weighted values based on the level of cholesterol and the presence or absence of the biomarker;
- determining a dosage of a drug for reducing cholesterol based on the weighted value;
- and
- administering the dosage of the drug to the patient.
Dependencies are inferred from the claim text.